Published in *Medical Devices: Evidence and Research*

Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptor

St. Peter DM, Steger JS, Patnaik JL, Davis N, Kahook MY, Seibold LK

doi: 10.2147/MDER.S397654. Published Apr 2023.



Nanodropper extends bottle-life by 2.6x

Published in *Ophthalmology*

Randomized Trial to Evaluate the Efficacy of the Nanodropper Device for Pupillary Dilation and Cycloplegia in Children

Hoppe CB, Yonamine S, Kao BW, Turner ML, Ou Y, Han Y, Keenan JD, Oatts JT

doi: 10.1016/j.ophtha.2022.10.016. Published Mar 2023.

Clinicaltrials.gov: NCT05274321



In pediatric eyes:

Non-inferiority of mydriatic microdrops established for maximum pupil diameter

Published in *Clinical Ophthalmology*

The Effect of Eyedrop Size on Pupillary Dilation Using the Nanodropper Bottle Adapter

Chow A, Choi J, Bacharach J

doi: 10.2147/OPTH.S504416. Published Apr 2025.

Clinicaltrials.gov: NCT06689904



In adult eyes:

Non-inferiority of mydriatic microdrops established for mean pupil diameter

Published in *Ophthalmology*

An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper®

Steger JS, Durai I, Odayappan A, Raman R, Sruthi T, Song AJ, Puthuran G, Venkatesh R, Colantuoni E, Robin AL

doi: https://doi.org/10.1016/j.ophtha.2024.03.012. Published Mar 2024.

Clinicaltrials.gov: NCT05181046





- No between-group difference in IOP at any time point
- Microdrops reduced heart rate significantly less than conventional drops

Presented at

Twelve-Week Randomized, Controlled, Non-Inferiority Trial Evaluating the Safety and Efficacy of IOP-Lowering Microdrops Administered with the Nanodropper® Adaptor in Glaucoma Patients

Steger JS, Capó-Aponte JE, Papp A, Schulte AJ, Song AJ, Colantuoni E, Kelstrom JC

Manuscript in preparation

Clinicaltrials.gov: NCT05844384

Superior IOP control



Reduced Adverse Events



Minimized EBE Events

(Early Bottle Exhaustion)



Conventional Microdrops

n = 30 in conventional drop group, 29 in Nanodropper group; Error bars: Mean ± SEM; * p<0.05.

At 12 weeks, in stable glaucoma patients:

- Non-inferiority and superiority of microdrops established
- Microdrops decreased IOP from baseline by 1.6 mm Hg
- Microdrops decreased EBE prevalence by 80% and AE prevalence by 67%

← Download a PDF copy or access full publications at: **nanodropper.com/pubs**

Learn more: nanodropper.com
Connect: pro@nanodropper.com